Dual protease inhibitor therapy in the management of the HIV-1
Authors:
- 1 December 2000
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 1 (7) , 1331-1342
Abstract
Throughout the first 20 years of the HIV-1 epidemic, there have been tremendous advances in the development of antiretroviral therapy (ART). In 1995, the availability of protease inhibitors (PI) as part of triple drug regimens resulted in durable viral suppression with an associated decline in HIV-1-related morbidity and mortality. Despite this early success, limitations of therapy have become apparent. In particular, the need for highly potent antiviral regimens, the importance of outstanding adherence to therapy, drug-related toxicity and the increasing problem of drug-drug and drug-food interactions. Dual PI therapy has been investigated with the hope of overcoming these problems. Select PI combinations may result in synergistic antiviral activity with enhanced viral suppression. Moreover, the ability of select agents to inhibit the cytochrome P450 (CYP450) system results in pharmacologic enhancement that allows for dosing with fewer pills on a less frequent basis, both of which can enhance drug adherence. Furthermore, these pharmacologic interactions can overcome drug-drug and drug-food interactions. Finally, the ability to increase drug levels using certain PI combinations may allow for drug concentrations to exceed those needed to inhibit resistant strains of HIV-1. The rationale for using dual PI therapy, along with the results of clinical trials using various PI combinations in treatment-naïve and experienced patients, is reviewed in this article.Keywords
This publication has 17 references indexed in Scilit:
- Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot studyAIDS, 2000
- Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individualsAIDS, 2000
- The SPICE Study: 48-Week Activity of Combinations of Saquinavir Soft Gelatin and Nelfinavir With and Without Nucleoside AnaloguesJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- Activity of the Combination of Nelfinavir and Saquinavir against Human Immunodeficiency Virus after Failure of Prior Protease Inhibitor TherapyClinical Infectious Diseases, 1999
- Prospective Follow‐Up of 67 Indinavir‐Experienced Human Immunodeficiency Virus‐Infected and AIDS Patients Treated with the Ritonavir/Saquinavir CombinationClinical Infectious Diseases, 1999
- Ritonavir and saquinavir combination therapy for the treatment of HIV infectionAIDS, 1999
- Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir*Clinical Pharmacology & Therapeutics, 1998
- Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre studyBMJ, 1997
- Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral TherapyNew England Journal of Medicine, 1997
- Drug Interactions in Patients Infected with Human Immunodeficiency VirusClinical Infectious Diseases, 1996